Editas Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it will participate in two upcoming investor conferences. Details are as follows:

A live webcast of the presentation will be available on the Investors & Media section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.

About Editas MedicineAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com. 

Contacts

Media:Cristi Barnett   
(617) 401-0113[email protected]

Investors:Mark Mullikin(617) 401-9083[email protected]

You May Also Be Interested In

• Diamond Certified Resource Welcomes Four New Top Rated Companies in August 2026
• Dickey's Barbecue Pit Hosts End-of-Summer 'Cue-mmunity Appreciation Bash on September 5
• Austral Gold Announces Filing of 2026 Half Year Report